Latest ChromaDex Corp. Stories
IRVINE, Calif., April 5, 2012 /PRNewswire/ -- The U.S. Patent and Trademark Office has granted patent #8,133,917 pertaining to the ingredient pterostilbene, which is licensed exclusively to ChromaDex Corp. (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of BluScience (www.bluscience.com), its new line of dietary...
IRVINE, Calif., April 2, 2012 /PRNewswire/ -- ChromaDex Corp. (OTCBB: CDXC), an innovative natural products company and marketer of patented pTeroPure®, today announced that they have formed an exclusive collaboration with Platinum Performance® to create Platinum Longevity((TM)). This equine supplement features ChromaDex's novel ingredient pTeroGold that was launched earlier this month. (Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO) pTeroGold is a blend of...
IRVINE, Calif., Aug. 22, 2011 /PRNewswire/ -- ChromaDex® Corp. (OTCBB: CDXC), Alcone, an Omnicom Group Inc. company, and Chandler Chicco Agency, an inVentiv Health company, today announced that the companies are working together to develop market-leading communications for ChromaDex® to engage customers, consumers and media. These agency partnerships demonstrate ChromaDex's® commitment to raising consumer awareness of the health benefits and strong research supporting pTeroPure®...
IRVINE, Calif., July 13, 2011 /PRNewswire/ -- ChromaDex Corp. (OTCBB.:CDXC) today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR). "Despite its potential to deliver significant health benefits, nicotinamide riboside, or NR, is currently not available to the market as a dietary ingredient," said Frank L. Jaksch, Jr., CEO of ChromaDex. "The technology we have...
IRVINE, Calif., June 14, 2011 /PRNewswire/ -- ChromaDex Corp. (OTCBB: CDXC) today announced that it has released the company's new investor presentation. The presentation can be found at investors.chromadex.com. Company President William F. Spengler will be presenting this business outlook at the Accredited Members investment conference today at the Hyatt Regency Denver Tech Center in Denver, Colorado. For further details please visit their website at...
IRVINE, Calif. and OXFORD, Miss., June 9, 2011 /PRNewswire/ -- ChromaDex Corp. (OTCBB: CDXC) and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health...
The Blanket Purchase Agreement will expedite the purchasing process for groups within the National Institutes of Health. IRVINE, Calif., June 24 /PRNewswire-FirstCall/ -- ChromaDex Corp., (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, announced today that the National Institutes of Health established a Blanket Purchase Agreement (BPA) with the Company. The Agreement covers all products and services offered by ChromaDex. This includes...
Research will progress development of plant-based antioxidants for commercial production in pharmaceutical, nutraceutical, functional food, natural chemical and cosmetic products IRVINE, Calif., June 11 /PRNewswire-FirstCall/ --- ChromaDex Corp., (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, announced today that the National Science Foundation awarded the Company a $100,000 Small Business Innovation Research (SBIR) Grant to further the...
